In addition to wAIHA, sovleplenib is also being studied in immune thrombocytopenia (“ITP”). Positive results from ESLIM-01 ...

Hutchmed is preparing to file for approval of a drug for the rare autoimmune disorder warm antibody autoimmune haemolytic ...

Hutchmed has continued to test sovleplenib in wAIHA in parallel, culminating in the delivery of data from a Chinese phase 3 ...

HUTCHMED reported positive Phase 3 trial results for sovleplenib in autoimmune anemia, supporting a planned China drug filing ...

Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease - HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- HUTCHME ...

Chinese biopharma Hutchmed today announces that the Phase III registration part of the ESLIM-02 clinical trial of sovleplenib ...

The Hong Kong-based developer of treatments for cancer and immunological diseases said the trial in adults with warm antibody autoimmune hemolytic anaemia [wAIHA] in China met its primary endpoint of ...

Following the FDA approval of rilzabrutinib (Wayrilz; Sanofi) for immune thrombocytopenia (ITP), a rare autoimmune disorder, David Kuter, MD, DPhil, highlights the most pressing a ...

Investing.com -- HUTCHMED (NASDAQ:HCM) stock gained 1.9% in premarket trading Wednesday after the company announced that its Phase III trial of sovleplenib in patients with warm antibody autoimmune ...

According to DelveInsight’s latest analysis, Nipocalimab is expected to capture meaningful market share across both prevalent ...

Shares of HUTCHMED (NASDAQ:HCM) rose around 1.9% in premarket trading on Wednesday after the company reported positive Phase ...

What price would you pay for the chance of just a little more quality time with a loved one facing declining cognition from ...